Why is ruxolitinib uniquely suited to treat vitiligo compared to other JAK inhibitors?

Featuring Neal Bhatia, MD |

Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA

| Published March 03, 2025